Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma

Robert E. Sobol, Kerstin B. Menander, Sunil Chada, Dora Wiederhold, Beatha Sellman, Max Talbott, John J. Nemunaitis
doi: https://doi.org/10.1101/2021.01.06.20248743
Robert E. Sobol
1MultiVir Inc, Houston, Texas USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rsobol@multivir.com
Kerstin B. Menander
1MultiVir Inc, Houston, Texas USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sunil Chada
1MultiVir Inc, Houston, Texas USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dora Wiederhold
1MultiVir Inc, Houston, Texas USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beatha Sellman
1MultiVir Inc, Houston, Texas USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Max Talbott
1MultiVir Inc, Houston, Texas USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John J. Nemunaitis
2University of Toledo Medical Center, Eleanor N. Dana Cancer Center, Toledo, Ohio USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background We conducted a meta-analysis of previous adenoviral p53 (Ad-p53) treatment data in recurrent head and neck squamous cell carcinoma (HNSCC) patients to identify optimal Ad-p53 treatment methods for future clinical trials.

Methods The meta-analysis involved recurrent HNSCC patients treated with Ad-p53 for whom p53 genotyping and immunohistochemistry tumor biomarker studies had been performed (n = 70). Ad-p53 tumor treatment responses defined by RECIST 1.1 criteria were correlated with Ad-p53 dose and tumor p53 biomarkers. Gene expression profiles induced by Ad-p53 treatment were evaluated using the Nanostring IO 360 panel.

Results Ad-p53 dose based upon the injected tumor volume had a critical effect on tumor responses. All responders had received Ad-p53 doses greater than 7 × 1010 viral particles/cm3 of tumor volume. There was a statistically significant difference in tumor responses between patients treated with greater than 7 × 1010 viral particles/cm3 compared to patients treated at lower Ad-p53 doses (Tumor Response 31% (9/29) for Ad-p53 > 7 × 1010 viral particles/cm3 versus 0% (0/25) for Ad-p53 < 7 × 1010 viral particles/cm3; p = 0.0023). All responders were found to have favorable p53 biomarker profiles defined by less than 20% p53 positive tumor cells by immunohistochemistry (IHC), wild type p53 gene sequence or p53 deletions, truncations, or frame-shift mutations without functional p53 tetramerization domains. Preliminary gene expression profiling results revealed that Ad-p53 treatment increased Type I Interferon signaling, decreased TGF-beta and beta-catenin signaling resulting in an increased CD8+ T cell signature which are associated with increased responses to immune checkpoint blockade.

Conclusions Our findings have important implications for future p53 targeted cancer treatments and identify fundamental principles to guide Ad-p53 gene therapy. We discovered that previous Ad-p53 clinical trials were negatively impacted by the inclusion of patients with unfavorable p53 biomarker profiles and by under dosing of Ad-p53 treatment. Future Ad-p53 clinical trials should have favorable p53 biomarker profiles inclusion criteria and Ad-p53 dosing above 7 × 1010 viral particles/cm3 of injected tumor volume. Preliminary gene expression profiling identified p53 mechanisms of action associated with responses to immune checkpoint blockade supporting evaluation of Ad-p53 in combination with immune checkpoint inhibitors.

Competing Interest Statement

This work was supported by MultiVir Inc. Conflict of Interest RES, SC, KBM, MT, BS and DW had consulting relationships with MultiVir Inc. The remaining authors have no conflicts of interest to declare.

Clinical Trial

NCT03544723

Funding Statement

This work was supported by MultiVir Inc. Conflict of Interest RES, SC, KBM, MT, BS and DW had consulting relationships with MultiVir Inc. The remaining authors have no conflicts of interest to declare.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The studies involving human participants were reviewed and approved by the ethics committee of the University of Toledo and other clinical trial centers where the patients were treated. The patients/participants provided their written informed consent to participate in the clinical trials analyzed in this study.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data supporting the conclusions of this article are either incorporated in the manuscript, its supplemental section or available by the corresponding author upon reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 06, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
Robert E. Sobol, Kerstin B. Menander, Sunil Chada, Dora Wiederhold, Beatha Sellman, Max Talbott, John J. Nemunaitis
medRxiv 2021.01.06.20248743; doi: https://doi.org/10.1101/2021.01.06.20248743
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Meta-Analysis of Adenoviral p53 Gene Therapy Clinical Trials in Recurrent Head and Neck Squamous Cell Carcinoma
Robert E. Sobol, Kerstin B. Menander, Sunil Chada, Dora Wiederhold, Beatha Sellman, Max Talbott, John J. Nemunaitis
medRxiv 2021.01.06.20248743; doi: https://doi.org/10.1101/2021.01.06.20248743

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2154)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)